Tuesday, November 29, 2016

BRIEF-Novo Nordisk says Tresiba demonstrates safe cardiovascular profile

* Says Tresiba demonstrates a safe cardiovascular profile

and reduces the risk of severe hypoglycaemia compared to insulin

glargine u100 in the devote trial

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)